LDHAL6CP

Across TCGA pan-cancer cohorts, LDHAL6CP RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated LDHAL6CP data layer.

The strongest signal is observed in mesothelioma (MESO), where higher LDHAL6CP RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LDHAL6CP expression acts as an unfavorable survival marker.

MESO, ACC, and GBM are the cancer types where LDHAL6CP RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	III,IV	0.224	0.585	.013	54	view →
ACC	OS	Tertile	II,III,IV	0.264	0.782	<.001	54	view →
GBM	DFS	Tertile	All	0.059	0.248	.001	21	view →
LGG	DFS	Tertile	All	0.410	0.764	.008	18	view →
UCEC	DFS	Tertile	IV	0.206	0.704	.033	18	view →
LIHC	OS	Tertile	III,IV	0.238	0.551	.017	15	view →
SKCM	OS	Tertile	All	0.642	0.793	.026	9	view →
STAD	OS	Tertile	III,IV	0.336	0.548	.035	6	view →
LUAD	OS	Tertile	All	0.645	0.840	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

LDHAL6CP–MESO (OS)

Open the MESO breakdown →